TY - JOUR
T1 - Surfactant protein A alters endosomal trafficking of influenza A virus in macrophages
AU - Yau, Eric
AU - Yang, Linlin
AU - Chen, Yan
AU - Umstead, Todd M.
AU - Atkins, Hannah
AU - Katz, Zoe E.
AU - Yewdell, Jonathan W.
AU - Gandhi, Chintan K.
AU - Halstead, E. Scott
AU - Chroneos, Zissis C.
N1 - Funding Information:
This work was funded in part by PHS grant HL128746, Pennsylvania Department of Health, The Children’s Miracle Network, and the Department of Pediatrics Pennsylvania State University College of Medicine. Acknowledgments
Publisher Copyright:
Copyright © 2023 Yau, Yang, Chen, Umstead, Atkins, Katz, Yewdell, Gandhi, Halstead and Chroneos.
PY - 2023
Y1 - 2023
N2 - Influenza A virus infection (IAV) often leads to acute lung injury that impairs breathing and can lead to death, with disproportionate mortality in children and the elderly. Surfactant Protein A (SP-A) is a calcium-dependent opsonin that binds a variety of pathogens to help control pulmonary infections by alveolar macrophages. Alveolar macrophages play critical roles in host resistance and susceptibility to IAV infection. The effect of SP-A on IAV infection and antiviral response of macrophages, however, is not understood. Here, we report that SP-A attenuates IAV infection in a dose-dependent manner at the level of endosomal trafficking, resulting in infection delay in a model macrophage cell line. The ability of SP-A to suppress infection was independent of its glycosylation status. Binding of SP-A to hemagglutinin did not rely on the glycosylation status or sugar binding properties of either protein. Incubation of either macrophages or IAV with SP-A slowed endocytic uptake rate of IAV. SP-A interfered with binding to cell membrane and endosomal exit of the viral genome as indicated by experiments using isolated cell membranes, an antibody recognizing a pH-sensitive conformational epitope on hemagglutinin, and microscopy. Lack of SP-A in mice enhanced IFNβ expression, viral clearance and reduced mortality from IAV infection. These findings support the idea that IAV is an opportunistic pathogen that co-opts SP-A to evade host defense by alveolar macrophages. Our study highlights novel aspects of host-pathogen interactions that may lead to better understanding of the local mechanisms that shape activation of antiviral and inflammatory responses to viral infection in the lung.
AB - Influenza A virus infection (IAV) often leads to acute lung injury that impairs breathing and can lead to death, with disproportionate mortality in children and the elderly. Surfactant Protein A (SP-A) is a calcium-dependent opsonin that binds a variety of pathogens to help control pulmonary infections by alveolar macrophages. Alveolar macrophages play critical roles in host resistance and susceptibility to IAV infection. The effect of SP-A on IAV infection and antiviral response of macrophages, however, is not understood. Here, we report that SP-A attenuates IAV infection in a dose-dependent manner at the level of endosomal trafficking, resulting in infection delay in a model macrophage cell line. The ability of SP-A to suppress infection was independent of its glycosylation status. Binding of SP-A to hemagglutinin did not rely on the glycosylation status or sugar binding properties of either protein. Incubation of either macrophages or IAV with SP-A slowed endocytic uptake rate of IAV. SP-A interfered with binding to cell membrane and endosomal exit of the viral genome as indicated by experiments using isolated cell membranes, an antibody recognizing a pH-sensitive conformational epitope on hemagglutinin, and microscopy. Lack of SP-A in mice enhanced IFNβ expression, viral clearance and reduced mortality from IAV infection. These findings support the idea that IAV is an opportunistic pathogen that co-opts SP-A to evade host defense by alveolar macrophages. Our study highlights novel aspects of host-pathogen interactions that may lead to better understanding of the local mechanisms that shape activation of antiviral and inflammatory responses to viral infection in the lung.
UR - http://www.scopus.com/inward/record.url?scp=85150494488&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85150494488&partnerID=8YFLogxK
U2 - 10.3389/fimmu.2023.919800
DO - 10.3389/fimmu.2023.919800
M3 - Article
C2 - 36960051
AN - SCOPUS:85150494488
SN - 1664-3224
VL - 14
JO - Frontiers in immunology
JF - Frontiers in immunology
M1 - 919800
ER -